KCPG
CLVS

Kavar Capital Partners Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Kavar Capital Partners Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4
Closed – – 551
2015
Q2 		$0 Buy
+4
New +$342 ﹤0.01% 542

Other funds holding CLVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Kavar Capital Partners Group's CLVS Position: Q3 2015 in Review

Kavar Capital Partners Group sold out of Clovis Oncology, Inc. (CLVS) in Q3 2015, closing a stake of 4 shares.

Kavar Capital Partners Group first reported a position in CLVS in Q2 2015 and held it in 1 quarter. The position peaked at $0 in Q2 2015. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2015.

  • Kavar Capital Partners Group reported no remaining Clovis Oncology, Inc. position as of Q3 2015 after selling out during the quarter.
  • Kavar Capital Partners Group sold 4 Clovis Oncology, Inc. shares in Q3 2015.
  • Kavar Capital Partners Group first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 1 quarter.
  • Kavar Capital Partners Group's Clovis Oncology, Inc. position peaked at $0 in Q2 2015.
  • 192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2015.

Based on Kavar Capital Partners Group's 13F filing for Q3 2015, filed 1 May 2019.